Michelle C. Juarez

Michelle C. Juarez

Auto-generated profile, based on publicly available information

Michelle C. Juarez

The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MJMichelle C. Juarez
Michelle C. Juarez
LILisa Ishii
Lisa Ishii
JNJason C. Nellis
Jason C. Nellis
KBKristin Bater
Kristin Bater
PHPauline Huynh
Pauline Huynh
MIMasaru Ishii
Masaru Ishii

29 October 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
DLDavid Liao
David Liao
LILisa E. Ishii
Lisa E. Ishii
LCLena W. Chen
Lena W. Chen
JCJonlin Chen
Jonlin Chen
MJMichelle Juarez
Michelle Juarez
MIMasaru Ishii
Masaru Ishii

6 March 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
MJMichelle C. Juarez
Michelle C. Juarez
SKShawn G. Kwatra
Shawn G. Kwatra
Lichen simplex chronicus (LSC) is a disorder characterized by thickened areas of skin from repeated rubbing or scratching. The multifactorial nature of LSC makes management difficult and there are currently no evidence-based guidelines for treatment. We conducted a systematic review of the literature to evaluate treatments for LSC and provide an evidence-based summary of the current treatments as well as highlight novel therapies. A total of 21 studies were included which comprised 682 patients with LSC involving various areas. The most robust evidence was seen with the use of topical corticosteroids (n = 7 RCTs) and limited data suggest benefit with other treatments such as topical immunomodulators, topical antipruritic agents, oral antihistamines, antiepileptics and antidepressants. We also discuss novel treatment approaches using transcutaneous electrical nerve stimulation, focused ultrasound, and phototherapy. Despite emerging evidence there remains a paucity of high-quality studies supporting treatments for LSC and larger controlled trials are needed.

15 February 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
NCNicolas Coudray
Nicolas Coudray
MJMichelle C. Juarez
Michelle C. Juarez
MCMaressa C. Criscito
Maressa C. Criscito
AQAdalberto Claudio Quiros
Adalberto Claudio Quiros
RWReason Wilken
Reason Wilken
JCJohn A Carucci
John A Carucci
Primary cutaneous squamous cell carcinoma (cSCC) is responsible for ~10,000 deaths annually in the United States. Stratification of risk of poor outcome at initial biopsy would significantly impact clinical decision-making during the initial post operative period where intervention has been shown to be most effective. Using whole-slide images (WSI) from 163 patients from 3 institutions, we developed a self supervised deep-learning model to predict poor outcomes in cSCC patients from histopathological features at initial diagnosis, and validated it using WSI from 563 patients, collected from two other academic institutions. For disease-free survival prediction, the model attained a concordance index of 0.73 in the development cohort and 0.84 in the Mayo cohort. The model’s interpretability revealed that features like poor differentiation and deep invasion were strongly associated with poor prognosis. Furthermore, the model is effective in stratifying risk among BWH T2a and AJCC T2, known for outcome heterogeneity.

23 August 2022 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
WNWilliam J. Nahm
William J. Nahm
MJMichelle Juarez
Michelle Juarez
JWJulie Wu
Julie Wu
Randie KimRandie Kim
Randie Kim

13 December 2023 in Research Square
Verified
Preprint
Open access
PDF file
JCJohn A Carucci
John A Carucci
NCNicolas Coudray
Nicolas Coudray
MJMichelle Juarez
Michelle Juarez
MCMaressa Criscito
Maressa Criscito
AQAdalberto Quiros
Adalberto Quiros
ATAristotelis Tsirigos
Aristotelis Tsirigos
Primary cutaneous squamous cell carcinoma (cSCC) is responsible for ~ 10,000 deaths annually in the United States. Stratification of risk of poor outcome (PO) including recurrence, metastasis and disease specific death (DSD) at initial biopsy would significantly impact clinical decision-making during the initial post operative period where intervention has been shown to be most effective.. In this multi-institutional study, we developed a state-of-the-art self-supervised deep-learning approach with interpretability power and demonstrated its ability to predict poor outcomes of cSCCs at the time of initial biopsy. By highlighting histomorphological phenotypes, our approach demonstrates that poor differentiation and deep invasion correlate with poor prognosis. Our approach is particularly efficient at defining poor outcome risk in Brigham and Women’s Hospital (BWH) T2a and American Joint Committee on Cancer (AJCC) T2 cSCCs. This bridges a significant gap in our ability to assess risk among T2a/T2 cSCCs and may be useful in defining patients at highest risk of poor outcome at the time of diagnosis. Early identification of highest-risk patients could signal implementation of more stringent surveillance, rigorous diagnostic work up and identify patients who might best respond to early postoperative adjunctive treatment.